The rule of five should not impede anti-parasitic drug development.
- Author(s): McKerrow, James H
- Lipinski, Christopher A
- et al.
Published Web Locationhttps://doi.org/10.1016/j.ijpddr.2017.05.003
The "rule of 5" has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development. However the authors of the original paper never intended for "double cutoffs" to preclude development of new drug leads for parasitic diseases.